7 search results
"Biogen revitalizes hope for Alzheimer’s therapy, but their work highlights why we still need greater selectivity."
To truly understand the intricacies of pathogenic bacteria, we need to combine “pure” and translational research.
China drafts new gene-editing regulations – but concerns over their enforcement remain.
We should be thrilled with the success of the approved CD-19 CAR-T therapies. But the field is still young, and we are only scratching the surface.
How will the storm whipped up by He Juinkai’s flagrant disregard for medical ethics affect the wider ambitions of the gene-editing field?
We don’t fully understand how probiotics affect cancer patient prognosis, so they should be approached with caution – at least for now.
As healthcare systems across the globe feel the strain of an increasing (and aging) population, we need someone – or rather something – to lend a help
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.